Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
 logo final copy.png)
The Hippocratic Editorial and VT team. Please send your suggestions to [email protected]
Latest posts by Hippocratic Post (see all)
- Gut microbiome could delay onset of type 1 diabetes - 3rd April 2025
- The da Vinci 5 Robot Is Set To Transform Bariatric Care: - 31st March 2025
- Beyond money: the hidden drivers fuelling child food insecurity - 31st March 2025
